Decreased Survival of Invasive Ductal Breast Cancer Patients With Two Macrometastatic Lymph Nodes Among Few Resected Ones: Should Current Sentinel-Lymph-Node Guidelines Be Revised?

breast neoplasm lymph node metastasis neoplasm staging nomograms sentinel lymph node biopsy

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 19 02 2021
accepted: 02 07 2021
entrez: 5 8 2021
pubmed: 6 8 2021
medline: 6 8 2021
Statut: epublish

Résumé

Sentinel-lymph-node (SLN) biopsy (SLB) is an efficient and safe axillary surgical approach with decreased morbidity than total axillary lymph node dissection (ALND) in initial patients (T1-T2). Current guidelines strongly suggest avoiding completion of ALND in patients with one or two positive SLNs that will be submitted to whole-breast radiation therapy, but must be done when three SLNs are affected. We performed a SEER-based study with breast invasive ductal carcinoma patients treated between 2010 and 2015. Optimal cutoffs of positive LNs predictive of survival were obtained with ROC curves and survival as a continuous variable. Bias was reduced through propensity score matching. Cox regression was employed to estimate prognosis. Nomograms were constructed to analyze the predictive value of clinicopathological factors for axillary burden. Of 43,239 initial patients that had one to three analyzed LNs, only 425 had two positive LNs and matched analysis demonstrated no survival difference versus pN2 patients [HR: 0.960 (0.635-1.452), Macrometastasis of two LNs is a poor prognostic factor, similar to pN2, in SLNB (-like) patients; more extensive studies including preconized therapies must be done in order to corroborate or refute the resistance of this prognostic difference in patients with two macrometastatic lymph nodes within few resected.

Identifiants

pubmed: 34350113
doi: 10.3389/fonc.2021.669890
pmc: PMC8327777
doi:

Types de publication

Journal Article

Langues

eng

Pagination

669890

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 Luz, Araújo and Silva.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Arch Surg. 2004 Jun;139(6):648-51
pubmed: 15197092
Cancer Manag Res. 2019 Jun 28;11:5765-5775
pubmed: 31303789
J Clin Oncol. 2014 May 1;32(13):1365-83
pubmed: 24663048
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
JAMA Surg. 2021 Jul 1;156(7):628-637
pubmed: 33950173
ISRN Oncol. 2011;2011:645450
pubmed: 22091427
Clin Breast Cancer. 2019 Feb;19(1):e101-e115
pubmed: 30502219
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
Breast Care (Basel). 2021 Apr;16(2):135-143
pubmed: 34002112
BMC Cancer. 2018 Feb 9;18(1):171
pubmed: 29426294
ANZ J Surg. 2005 Jan-Feb;75(1-2):27-31
pubmed: 15740512
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120
pubmed: 29132568
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Br J Radiol. 2013 Mar;86(1023):20120601
pubmed: 23392193
Cancer. 2008 Jul 1;113(1):30-7
pubmed: 18457326
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
BMC Surg. 2015 Jun 30;15:79
pubmed: 26123412
Ann Med Surg (Lond). 2020 Jun 23;56:95-107
pubmed: 32637082
Med Care. 2016 Sep;54(9):e55-64
pubmed: 24638121
Ann Surg Oncol. 2010 Jul;17(7):1862-9
pubmed: 20162457
Crit Rev Oncol Hematol. 2017 Feb;110:74-80
pubmed: 28109407
Medicine (Baltimore). 2020 Aug 28;99(35):e21721
pubmed: 32871890
Front Oncol. 2021 Jan 26;10:605750
pubmed: 33575216
Am J Surg. 2007 Dec;194(6):860-4; discussion 864-5
pubmed: 18005785
Breast. 2020 Oct;53:143-151
pubmed: 32823167
Br J Surg. 2020 Nov;107(12):1615-1624
pubmed: 32492194
Arch Gynecol Obstet. 2009 Jan;279(1):23-8
pubmed: 18449551
Acta Oncol. 2020 Jun;59(6):689-695
pubmed: 32148141
Radiology. 2020 Jun;295(3):500-515
pubmed: 32315268
ESMO Open. 2021 Jun;6(3):100151
pubmed: 33984674
Int J Surg. 2017 Dec;48:275-280
pubmed: 29175020
BMC Cancer. 2019 Jun 25;19(1):626
pubmed: 31238899
Sci Rep. 2020 Sep 7;10(1):14684
pubmed: 32895434
Breast Cancer. 2018 Nov;25(6):629-638
pubmed: 29696563
J Clin Oncol. 2006 Apr 20;24(12):1814-22
pubmed: 16567771
PLoS One. 2013 Apr 23;8(4):e61410
pubmed: 23626682
Rev Col Bras Cir. 2017 Jul-Aug;44(4):391-396
pubmed: 29019543
J Clin Oncol. 2017 Feb 10;35(5):561-564
pubmed: 27937089
Am J Cancer Res. 2020 Apr 01;10(4):1045-1067
pubmed: 32368385
J Clin Oncol. 2006 Jun 20;24(18):2910-6
pubmed: 16782931
Crit Rev Oncol Hematol. 2018 Mar;123:83-94
pubmed: 29482783

Auteurs

Felipe A C Luz (FAC)

Center for Projects, Prevention and Research in Cancer at the Hospital do Câncer in Uberlândia, Uberlândia, Brazil.
Laboratory of Tumors Osteoimmunology and Immunology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil.

Rogério A Araújo (RA)

Laboratory of Tumors Osteoimmunology and Immunology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil.
Department of Clinical Medicine, Faculty of Medicine, Federal University of Uberlândia, Uberlândia, Brazil.

Marcelo J B Silva (MJB)

Laboratory of Tumors Osteoimmunology and Immunology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil.

Classifications MeSH